279 related articles for article (PubMed ID: 18824953)
21. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
Novak M; Schlagenhauf A; Bernhard H; Schweintzger S; Leschnik B; Muntean W
Blood Coagul Fibrinolysis; 2011 Oct; 22(7):588-92. PubMed ID: 21799400
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
23. Ex vivo coagulation test on tissue factor-expressing cells with a calibrated automated thrombogram.
Takamiya O; Sakata M
Lab Hematol; 2008; 14(4):39-44. PubMed ID: 19095614
[TBL] [Abstract][Full Text] [Related]
24. Thrombin generation determined by calibrated automated thrombography (CAT) in pediatric patients with congenital heart disease.
Koestenberger M; Cvirn G; Nagel B; Rosenkranz A; Leschnik B; Gamillscheg A; Beitzke A; Muntean W
Thromb Res; 2008; 122(1):13-9. PubMed ID: 17915295
[TBL] [Abstract][Full Text] [Related]
25. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
26. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
[TBL] [Abstract][Full Text] [Related]
27. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution.
De Smedt E; Wagenvoord R; Coen Hemker H
Thromb Haemost; 2009 Jan; 101(1):165-70. PubMed ID: 19132204
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
[TBL] [Abstract][Full Text] [Related]
29. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
30. Thrombin generation in paediatric patients with congenital heart disease. Determination by calibrated automated thrombography.
Koestenberger M; Cvirn G; Rosenkranz A; Leschnik B; Raith W; Muntean W
Hamostaseologie; 2008 Oct; 28 Suppl 1():S61-6. PubMed ID: 18958342
[TBL] [Abstract][Full Text] [Related]
31. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding.
Schols SE; van der Meijden PE; van Oerle R; Curvers J; Heemskerk JW; van Pampus EC
Thromb Haemost; 2008 Jan; 99(1):64-70. PubMed ID: 18217136
[TBL] [Abstract][Full Text] [Related]
32. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
Dinkelaar J; Molenaar PJ; Ninivaggi M; de Laat B; Brinkman HJ; Leyte A
J Thromb Haemost; 2013 Jun; 11(6):1111-8. PubMed ID: 23578206
[TBL] [Abstract][Full Text] [Related]
33. Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor-activated plasma.
Nieuwenhuys CM; Feijge MA; Béguin S; Heemskerk JW
Thromb Haemost; 2000 Dec; 84(6):1045-51. PubMed ID: 11154112
[TBL] [Abstract][Full Text] [Related]
34. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
Fenyvesi T; Jörg I; Weiss C; Harenberg J
Thromb Res; 2003; 111(1-2):89-94. PubMed ID: 14644085
[TBL] [Abstract][Full Text] [Related]
35. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Seo JW; Kim HK; Kim JE; Park S; Cho HI
Thromb Res; 2009 Feb; 123(4):565-72. PubMed ID: 18479738
[TBL] [Abstract][Full Text] [Related]
36. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.
Brodin E; Seljeflot I; Arnesen H; Hurlen M; Appelbom H; Hansen JB
Thromb Res; 2009 Feb; 123(4):573-9. PubMed ID: 18474393
[TBL] [Abstract][Full Text] [Related]
37. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
38. Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).
Gardiner C; Machin SJ; Mackie IJ
Int J Lab Hematol; 2008 Aug; 30(4):261-8. PubMed ID: 18665822
[TBL] [Abstract][Full Text] [Related]
39. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
40. The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies.
Membre A; Wahl D; Latger-Cannard V; Max JP; Lacolley P; Lecompte T; Regnault V
Haematologica; 2008 Apr; 93(4):566-73. PubMed ID: 18322249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
